Yarrow Bioscience, Inc. (Nasdaq: YARW) released its financial results for the third quarter ended September 30, 2026, alongside a corporate update. The company reported a net loss of $9.7 million for the quarter, with research and development expenses totaling $5.3 million and general and administrative expenses totaling $5.5 million.
As of September 30, 2026, Yarrow reported cash and cash equivalents of $268.9 million. The company stated that this cash balance, which includes net proceeds from a recent public offering, is expected to fund operations into 2030. As of the same date, the company had approximately 11.5 million shares of common stock issued and outstanding.
In September 2026, Yarrow completed an underwritten public offering of 6,634,615 shares of common stock. The aggregate gross proceeds from this offering were approximately $172.5 million, before deducting underwriting discounts and commissions and other offering expenses.
On the clinical development front, Yarrow is enrolling patients in the Phase 2a portion of the DIRECTION-GD trial. This trial is evaluating YB-101, a potential first-in-class anti-TSHR antibody, in patients with Graves’ disease, with or without concomitant thyroid eye disease. Topline results from the Phase 2a portion are expected in the second half of 2027. The company noted that YB-101 has received Fast Track Designation from the U.S. Food and Drug Administration.
